Drug-induced long QT and torsade de pointes: recent advances.
Kannankeril PJ, Roden DM.
Curr Opin Cardiol. 2007 Jan;22(1):39-43. doi: 10.1097/HCO.0b013e32801129eb.
Seizure-induced Torsades de pointes:In a canine drug-induced long-QT1 model.
van der Linde H, Kreir M, Teisman A, Gallacher DJ.
J Pharmacol Toxicol Methods. 2021 Sep-Oct;111:107086. doi: 10.1016/j.vascn.2021.107086. Epub 2021 Jun 10.
Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G, Carmel NN, Lotan D, Kremer A, Justo D.
Z Gerontol Geriatr. 2018 Jan;51(1):41-47. doi: 10.1007/s00391-016-1155-5. Epub 2016 Nov 22.
Managing drug-induced QT prolongation in clinical practice.
Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH.
Postgrad Med J. 2021 Jul;97(1149):452-458. doi: 10.1136/postgradmedj-2020-138661. Epub 2020 Oct 29.
Drug-induced long QT syndrome and torsade de pointes.
Morissette P, Hreiche R, Turgeon J.
Can J Cardiol. 2005 Aug;21(10):857-64.
Drug-induced torsade de pointes. Incidence, management and prevention.
Faber TS, Zehender M, Just H.
Drug Saf. 1994 Dec;11(6):463-76. doi: 10.2165/00002018-199411060-00007.
Drug-induced torsade de pointes: from molecular biology to bedside.
Tamargo J.
Jpn J Pharmacol. 2000 May;83(1):1-19. doi: 10.1254/jjp.83.1.
Predicting drug-induced QT prolongation and torsades de pointes.
Roden DM.
J Physiol. 2016 May 1;594(9):2459-68. doi: 10.1113/JP270526. Epub 2016 Jan 18.
Detection of Clinically Significant Drug-Drug Interactions in Fatal Torsades de Pointes: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.
Ji H, Gong M, Gong L, Zhang N, Zhou R, Deng D, Yang Y, Song L, Jia Y.
J Med Internet Res. 2025 Mar 25;27:e65872. doi: 10.2196/65872.
Pharmacological treatment of acquired QT prolongation and torsades de pointes.
Thomas SH, Behr ER.
Br J Clin Pharmacol. 2016 Mar;81(3):420-7. doi: 10.1111/bcp.12726. Epub 2015 Oct 26.
